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We tested the cytotoxic action of 8-hydroxyguanine
(8ohG) by observing the viability of several leukemic cell
lines (KG-1, U937, Jurkat and K 562) in the presence of
8-hydroxydeoxyguanosine (8ohdG), a nucleoside of
8ohG. It was found that 8ohdG showed cytotoxic action
only to KG-1 and that only KG-1 showed a homozygous
arginine 209 to glutamine mutation in the hOGG1 gene
with an almost negligible hOGG1 enzyme activity.
Possibly, the selective cytotoxicity in 8ohdG to KG-1
may be due to its low capacity to cope with an increase
in the 8ohG level in DNA resulting from the incorpora-
tion of 8ohdG present in the culture media. The
mutational impairment of hOGG1 in KG-1 is the first
report in leukemic cell lines. Using KG-1 with impaired
hOGG1, we demonstrated cytotoxicity of 8ohdG
probably due to its incorporation into cellular DNA.
This new property of KG-1 may allow it to serve as an
useful tool for studies of OGG1, oxidative DNA damage
and the cytotoxic action of 8ohG. Oncogene (2000) 19,
4476 – 4479.
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We tested the cytotoxicity of 8-hydroxyguanine (8ohG)
by observing whether growths of four leukemia cell
lines (KG-1, U937, Jurkat and K562) are aected when
they are cultured in the presence of 8-hydroxydeox-
yguanosine (8ohdG, a nucleoside of 8ohG). The
cytotoxicity of 8ohG was assumed by the fact that
8ohG is a base analog, many of which have proven to
be cytotoxic and are used in anti-cancer therapy
(Calabresi and Chabner, 1991).
In this investigation, we found that 8ohdG inhibited
the growth of only KG-1 and no other cell line tested
(Figure 1a). Why does this base analog exhibit
dierential or selective cytotoxicity? We assume that
the impaired repair activity of 8ohG is one of the
likeliest reasons. It is possible that the exogeneous
8ohdG added to the culture media might be incorpo-
rated in cellular DNA. If cells have a normal repair
activity, they can cope with the increase of 8ohG in
DNA resulting from such an incorporation by
removing the modified guanine residues from DNA.
However, cells without such repair ability cannot
survive the resulting accumulation of 8ohG in DNA.
We found an enzyme which repairs 8ohG in DNA, by
removing 8ohG as a free base (glycosylase activity) and
then cleaving the phosphodiester bonds 3’ and 5’ to the
resulting AP (AP lyase activity) site in E. coli (Chung et
al., 1991a; Tchou et al., 1991) and mammals (Chung et
al., 1991b; Yamamoto et al., 1992; Lee et al., 1993).
Recently, genes have been found which encode this
enzyme in yeast (OGG1) (Auret Van Der Kemp et al.,
1996; Nash et al., 1996) and human (hOGG1; human
analog of yeast OGG1) (Radicella et al., 1997; Roldan-
Arjona et al., 1997; Arai et al., 1997; Aburatani et al.,
1997; Lu et al., 1997). In order to elucidate a possible
mechanism for the observed dierential cytotoxicity of
the exogenous 8ohdG, we compared the status of the
hOGG1 gene in four leukemic cell lines in terms of
enzyme activity and gene sequence, and also tested the
incorporation of the exogenous 8ohdG into DNA of
cells impaired in hOGG1 function.
As mentioned above, Figure 1a shows selective or
dierential cytotoxicity of 8ohdG as indicated by the
observation that 8ohdG added to media inhibited the
growth of only KG-1 of the four cell lines tested. In
order to determine a possible reason for this selective
cytotoxicity, we compared the activity of the hOGG1
enzyme of KG-1 with that of U937, which is one of the
cell lines resistant to the cytotoxic action of 8ohdG.
The hOGG1 enzyme was assayed in terms of
glycosylase activity (Figure 2a) and AP lyase activity
(Figure 2b). As is shown in Figure 2, both glycosylase
and AP lyase activities were almost negligible in KG-1
compared to U937. The other two resistant cell lines
showed activities almost identical to those of U937
(data not shown). KG-1 and U937 showed no
dierence in the band densities in Western blot using
a polyclonal rabbit antibody to hOGG1 protein
(Figure 3). However, we found a point mutation in
the hOGG1 gene of KG-1, which was CGA?CAA
(arginine?glutamine) at codon 229 of exon 4 (Table
1). Thus, the activity loss of the hOGG1 enzyme in
KG-1 possibly may be due to mutational impairment
and not to the low level of the enzyme protein. In
Figure 1b, we demonstrated that the exogeneous
8ohdG was incorporated into DNA of KG-1 but not
into that of U937. It is of importance to note that
basal level of 8ohdG in DNA of KG-1 was higher than
that in DNA of U937. This 229 mutation was
homozygous since all the exon 4s obtained from more
than 10 subcloned colonies showed the CAA sequence.
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Figure 1 Cytotoxic eect of exogenous 8ohdG on various leukemic cell lines and its incorporation into cellular DNA. (a) Jurkat
(human T-acute lymphoid leukemic cells), U937 (human monocytic leukemic cells), K562 (human myelomonocytic leukemic cells)
and KG-1 (human acute myelocytic leukemic cells) were grown in RPMI 1640 containing 2 mM glutamine, 10% heat-inactivated
fetal calf serum, penicillin (100 units/ml) and streptomycin (100 mg/ml) at 378C in 5% CO2. Cells at the exponential phase were
collected and transferred into each well (about 104 – 105 cells in 180 ml/well). The cells were incubated for 4 days in the presence of
various amounts of 8ohdG (0 – 200 mg/ml) at 378C in 5% CO2 in a total reaction volume of 200 ml. The cytotoxic eect of 8ohdG
was assayed using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma Chemical Co., St. Louis, MO, USA)
as described previously (Carmichael et al., 1987). Briefly, MTT (0.1 mg/well; 50 ml of 2 mg/ml MTT solution) was added to each
well. After 4 h incubation, plates were centrifuged at 800 g for 5 min and supernatants were aspirated. The formazan crystals in
each well were dissolved in 150 ml DMSO and the A540 was read on a scanning multiwell spectrophotometer (Molecular Device Co.,
Sunnyvale, CA, USA). The results presented are the mean+s.e. of three independent experiments. (b) During the culture in the
presence of various concentrations of 8ohdG, cells were harvested at times indicated. DNA was isolated from the harvested cells
with genomic DNA extraction kit (Wako junyaku, Tokyo, Japan) and assayed for 8ohdG as previously described (Kasai et al.,
1986). Data are means of the two experiments
Figure 2 Activity of hOGG1 enzyme in KG-1 and U937. KG-1 and U937 were cultured as described in Figure 1. The cells at the
exponential phase were centrifuged (800 g for 5 min). Cell pellets were then suspended in 2 volumes of homogenation buer (50 mM
Tris-HCl, 50 mM KCl, 1 mM EDTA, 5% glycerol and 0.05% 2-mercaptoethanol, pH 7.5) and homogenized. The homogenates were
mixed with streptomycin (final concentration 1.5%) to remove nucleic acids. Supernatants obtained by centrifugation were dialyzed
extensively against the homogenation buer and used as cell extracts for the hOGG1 activity assay. All the procedures were
performed below 48C and the protein amount was determined using the bicinchoninic acid method (Smith et al., 1985) using bovine
serum albumin as a standard. The enzyme was assayed for glycosylase activity to remove 8ohG from DNA strand, and for AP lyase
activity to cleave the DNA strand at the site of 8ohG. (a) glycosylase activity :A 21-mer oligonucleotide containing 8ohG (5’-
CAGCCAATCAGTG*CACCATTC-3’; G*; 8ohG) was chemically synthesized (The Midland Certified Reagent Co., Medland, TX,
USA). The oligonucleotide was annealed with its complementary oligonucleotide and the resulting duplex DNA was used as the
assay substrate. The duplex substrate DNA (20 pmol) was incubated with the cell extracts (2 mg protein) at 308C for 2 h in 1 ml of
reaction mixture (50 mM Tris-HCl, 50 mM KCl and 1 mM EDTA, pH 7.5). The reaction was terminated by heating at 908C for
3 min. The amount of 8ohG released into the reaction media was assayed according to the procedure described by Lee et al. (1993).
Results quoted are the mean+s.e. of two independent experiments. (b) AP lyase activity : The above 21 mer oligonucleotide
containing 8ohG and the same 21 mer but containing G at the site of 8ohG were labeled with 32P at the 3’ terminus according to the
method of Tu and Cohen (1980) but with slight modification, as described previously (Kim et al., 1996) and annealed with the
unlabeled complementary oligonucleotide. Each of the duplex DNAs (0.2 pmol) was incubated with the cell extract (50 mg protein)
in 20 ml of 50 mM Tris-HCl, 50 mM KCl, and 1 mM EDTA (pH 7.5) at 378C for 15 min. Cleaved substrate DNA fragments at the
8ohG position were detected autoradiographically as described previously (Chung et al., 1991a; Kim et al., 1996). G*/C : duplex
DNA containing 8ohG and G/C : duplex DNA containing G at the position of 8ohG. The arrow indicates the fragment cleaved at
the 8ohG position. Only the cell extract of U937 but not KG-1 was able to cleave the G*/C. As expected, G/C was not cleaved by
either of the cell extracts
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Mutations in the hOGG1 gene have been reported in
a small but significant number of cells, which are
mostly of tumor origin, and the properties and
consequences of these mutations have been studied. A
serine 326 to cystein mutation (polymorphism) found
in healthy individuals and gastric patients diminishes
enzyme activity very slightly (Kohno et al., 1998;
Dherin et al., 1999), and also has no association with
gastric carcinogenesis (Shinmura et al., 1998). An
arginine 154 to histidine mutation found in MKN1
(Shinmura et al., 1998), a stomach cancer cell line, does
not aect the normal antimutagenic ability to remove
8ohG paired to C, but causes a substantial increase in
its ability to remove 8ohG paired with bases other than
C, particularly A (Bruner et al., 2000), which appears
to make this enzyme promutagenic. But an arginine
131 to glutamine mutation discovered in a primary
lung cancer makes the enzyme devoid of the activity to
remove 8ohG paired to C (Chevillard et al., 1998). The
guanidine group of arginine 131 appears to be involved
extensively in hydrogen bonding interactions with
neighboring residues. The smaller and less polar side
chain of glutamine is not expected to participate in this
interaction as eectively as that of arginine, which has
an adverse eect on protein folding.
Recently, we (Choi et al., 1999) found an arginine 304
to tryptophan mutation in the two strains (SAMP1 and
SAMP8) of senescence-accelerated mice (SAM) expres-
sing a senescence-prone phenotype. This mutant enzyme
of the SAMP strains has very low activity (about 10% of
that of SAMR1, a SAM with the normal aging
phenotype) and is thermolabile. Bruner et al. (2000)
suggested that the hydrocarbon side chain of arginine
304 is packed into the protein core with the polar head
group extruded into a water filled channel. The
interaction of the tryptophan side chain probably
disrupts the optimal packing of the protein core due to
an increase in steric bulk. In this study, another mutation
involving arginine?glutamine was also found in KG-1
but at position 229. The role of arginine 229 in hOGG1
has not been elucidated. However, this mutation is
evidently expected to impair the enzyme activity since the
polar and larger side chain of arginine is replaced by the
less polar and smaller one of glutamine.
In this communication, we report two important
findings. One is that KG-1 has functional loss of the
hOGG1 enzyme due to the point mutation of
CGA?CAA (arginine?glutamine) at codon 229. This
mutation at a newly identified site is a first report of
such in leukemia cell lines. Thus, we expect that KG-1
will serve as a useful model for studies on the roles of
OGG1 and 8ohG in leukemia genesis. The second
important finding is that exogeneous 8ohdG can be
incorporated into cellular DNA and cytotoxic, which,
however, were observed only in the cell having
impaired activity of the OGG1 enzyme. The causal
link of the deficiency of OGG1 activity to the
cytotoxicity of exogeneous 8ohdG was further sup-
ported by the finding that on the culture of 18 cell lines
(five cell lines with low activity of OGG1 and 13 cell
lines with normal activity) in the presence of 8ohdG,
growth inhibition was observed only in the five cell
lines with a lower activity of hOGG1 enzyme and not
in any of the 13 cell lines with normal activity (data
not shown). However, the incorporation of 8ohdG into
DNA of KG-1 observed in the study is in conflict with
the report (Hayakawa et al., 1995) showing that
guanylate kinase, which phosphorylates both GMP
and dGMP to the corresponding nucleoside dipho-
sphates, is totally inactive for 8-oxo-dGMP, which is
formed from 8ohdG. Probably, guanylate kinase of
KG-1 may also have a functional alteration which
allows this enzyme to resume the activity to 8-oxo-
dGMP. Now, we are studying the activity of guanylate
kinase of KG-1 toward 8-oxo-dGMP.
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